Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC
Conditions: NSCLC; Adenocarcinoma; Squamous Cell Carcinoma Interventions: Drug: Anlotinib combined with pemetrexed and carboplatin, phase I; Drug: Anlotinib combined with paclitaxel and carboplatin, phase I; Drug: Anlotinib combined with pemetrexed and carboplatin, phase II; Drug: Anlotinib combined with paclitaxel and carboplatin, phase II Sponsor: Chinese Academy of Medical Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Alimta | Cancer & Oncology | Carcinoma | Chemotherapy | Non-Small Cell Lung Cancer | Research | Study